Keywords: Genzyme, Preliminary 2010 results, Sanofi-Aventis, Merger talks

Genzyme posts record 4th-qtr 2010 revenues but cuts 2011 guidance, as Sanofi-Aventis talks continue

Article | 12 January 2011

Print This

Leading US biotech group Genzyme (Nasdaq: GENZ) - the subject of a hostile takeover bid from French drug major Sanofi-Aventis ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in